BioTime’s Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTimes subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New York City today.

Dr. Warshawsky will describe the origins of XenneX, a company that LifeMap has agreed to acquire, and the business strategy that led to its rapid rise to profitability. He will describe the GeneCards database (www.genecards.com) which is used as a research tool world-wide in academia, research hospitals, patent offices, and leading biotech and pharma companies. He will report that GeneCards enjoys more than 12 million page visits/year by hundreds of thousands of unique users, consistently in top positions for gene search results in Google.

Dr. Warshawsky will discuss LifeMaps work to build an integrated map of the thousands of cell types in human development, beginning with the fertilized egg and ending in the developed human. Combined with genomics information, the database is expected to become a road atlas of human biology benefiting medicine and research. In addition, LifeMap is developing its own proprietary technology to effectively analyze data gathered from the data bases for use in the development of cell-based therapies. LifeMap also plans to market a new disease database called MalaCards, which has been developed by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel and may be licensed to LifeMap from Yeda Research and Development Company Ltd, the Technology Transfer Company of the Weizmann Institute.

In addition to expanding LifeMaps data base offerings through the acquisition of XenneX, BioTime plans to make LifeMap the principal marketing subsidiary for BioTime research products, including ACTCellerate human progenitor cell lines, GMP human embryonic stem (hES) cell lines, hES cell lines carrying inherited genetic diseases, and ESpan growth media for progenitor cell lines for non-therapeutic uses. LifeMap will utilize its databases as part of its on-line marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.

Dr. Warshawsky will explain how, in a therapeutic discovery collaboration with BioTime, LifeMap scientists will utilize LifeMaps proprietary discovery platform and stem cell data base along with its newly acquired data base products as a discovery platform to aid in the development of ACTCelleratehuman progenitor cell lines into products for the treatment of human diseases, especially degenerative diseases that might be treatable by cell replacement therapies. Human therapeutic products require a high degree of purity to meet the hurdles of regulatory approval and acceptance in medical practice. ACTCellerate technology was invented as a means of generating human progenitor cells from hES cells in a scalable and highly purified state. The LifeMap discovery platform will be applied to select the progenitor cell lines that are most likely to be useful in developing cell based regenerative medicine therapies for various diseases.

Dr. Warshawskys presentation will be available on BioTimes web site http://www.biotimeinc.com as well as LifeMap Sciences' web site at http://www.lifemapsc.com.

About LifeMap Sciences, Inc.

LifeMap Sciences (LifeMap), http://www.lifemapsc.com, is developing a discovery platform, including a web-based database, to aid researchers in the use of embryonic stem cells, progenitor cells, and induced pluripotent stem cells for the development of new products and technologies in the emerging field of regenerative medicine. LifeMap Sciences intends to become the central knowledgebase for stem cell research and discovery of cell-based regenerative medicine therapeutic products. LifeMap Sciences' core technology and business is based on a state-of-the-art roadmap for stem cell research providing comprehensive coverage of embryonic stem cell biology. LifeMap has signed an agreement to acquire XenneX, a company with products that help organizations to optimize their efforts to develop innovative medical products and services. XenneX's customers include many of the world leading biotech and pharmaceutical companies, located in North America, Europe and Asia.

About BioTime, Inc.

Go here to read the rest:
BioTime’s Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development